Syntis Bio completed $33 million Series A Round funding
Sector:
Life Science
Biotech
07/01/2025
Boston, MA USA
Syntis Bio
completed $33 million Series A Round funding. Investors include
Cerberus Capital Management (lead), Mansueto Investments, Woori Venture Partners, BOLD Capital Partners, Safar Partners, Colorcon Ventures, Cerity Partners Ventures.
"We’re grateful for the continued support and enthusiasm of our new and existing investors, who share our vision to revolutionize both chronic and rare disease treatment through safe, effective oral therapies," said Rahul Dhanda, CEO and co-founder of Syntis Bio. "This oversubscribed Series A round coupled with these non-dilutive grants validates and accelerates the promise of SYNT-101 in obesity and, more broadly, our SYNT platform technology to unlock the small intestine’s full therapeutic potential to meaningfully improve human health."
About
Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for targeted activity in the small intestine, the body’s nexus for metabolic control, digestion and drug absorption. Alongside its lead obesity program, SYNT-101, the company is advancing a portfolio of therapies targeting orphan metabolic diseases and intestinal-related disorders.
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
